Is Eli Lilly and Company (LLY) One of the 10 Best Dividend Stocks to Buy According to D.E. Shaw?
Eli Lilly (LLY) was listed among D. E. Shaw’s “10 Best Dividend Stocks to Buy.” Jefferies raised its price target to $1,350 from $1,330 and kept a Buy rating after Lilly released full data from retatrutide studies TRIUMPH-1 (obesity) and TRANSCEND-T2D-1 (type 2 diabetes). Reuters said LLY shares rose 4% on June 8. In the obesity study, the 4 mg dose produced about 19% weight loss, with tolerability broadly as expected.
How this was made
The 30-second read
Why it matters
The combination of newly presented full clinical results and a Jefferies price-target increase is a direct catalyst for sentiment and positioning in Lilly’s obesity franchise.
Market read
Traders may treat the retatrutide efficacy/tolerability read-through and the analyst target raise as near-term drivers for LLY’s obesity-drug valuation narrative.
What to watch
The article doesn’t quantify trial endpoints beyond weight loss/tolerability, so investors may still discount durability, cardiometabolic outcomes, or longer-term discontinuation rates.
Background
The piece centers on Lilly’s retatrutide Phase 3 obesity and Type 2 diabetes programs, with full data presented at the ADA meeting and followed by sell-side commentary.
Ticker impact
Jefferies raised its price recommendation on Eli Lilly after full retatrutide TRIUMPH-1 and TRANSCEND-T2D-1 obesity/Type 2 diabetes data were released.
Bias toward continued upward momentum/valuation support, with volatility tied to perceived safety/tolerability at lower vs higher doses.
The article cites full study data (weight loss ~19% at 4 mg, tolerability broadly consistent) and a same-week Jefferies upgrade/target increase, both of which can re-rate near-term obesity-drug expectations.
Market effects
Strengthens sentiment for GLP-1/obesity pipeline competition and supports the broader weight-loss drug complex on perceived efficacy/tolerability improvements.
Primarily US large-cap pharma sentiment; could spill into US biotech/healthcare risk appetite.
Obesity Phase 3 read-through can influence global investor positioning in major obesity-drug developers.
Counterpoint
Safety observations at higher doses and the focus on specific dose performance could limit how much the market extrapolates to label-relevant outcomes.
Key entities
- companyEli Lilly and Company
US-listed pharma company whose retatrutide Phase 3 data and analyst target raise are discussed.
- drugretatrutide
Next-generation obesity/Type 2 diabetes candidate; full TRIUMPH-1 and TRANSCEND-T2D-1 data are highlighted.
- analyst_firmJefferies
Raised its price recommendation and reiterated Buy after the retatrutide data release.
